Solid Biosciences @Solid_Bio

As we head into the @ParentProjectMD (PPMD) Annual Conference, we are sharing the latest update with the Duchenne Community, including an overview of recent progress in our SGT-003 clinical development program. We are deeply grateful for our partnerships with patients, families and our clinical sites, and look forward to engaging at PPMD this weekend. Read more here: solidbio.com/letter-to-the-…

#TeamSolid was proud to take part in the @BAA's 10K, presented by Mass General Brigham Cancer Institute! All funds raised will support efforts to advance groundbreaking research, deliver leading-edge care, and improve outcomes for patients and families facing cancer. Congratulations to everyone who raced and thank you to the B.A.A. for bringing together such an incredible event and community. #BAA10K #MassGeneralCancerInstitute #CardiacHealth

We’re proud to be attending, sponsoring and exhibiting at @ParentProjectMD's 2026 Annual Conference, taking place June 25–27 in Orlando. This important meeting brings together the Duchenne community to connect, learn and discuss advancements toward new treatments. We look forward to engaging with patients, families, advocates, clinicians and partners throughout the conference. If you’re attending, stop by our exhibit table #4 to connect with the Solid Biosciences team. Learn more: parentprojectmd.org/events/ppmds-2… #PPMD2026

Our Head of Corporate Strategy and Business Development, Shuli Kulak, M.D., will participate in @IamBiotech's International Convention breakout session, At the Helm of Biopharma: Insights from Women Leading Science, Strategy, and Scale. To learn more about the session, visit: convention.bio.org/2026-sessions-… #BIO2026

Looking forward to the conversations and connections at #BIO2026 next week. If you’re in the genetic medicine space and want to chat about platform partnerships or our pipeline, let's find some time to connect in San Diego. #GeneTherapy #BiotechInnovation Reach us at [email protected] or through the BIO Partnering™ system, convention.bio.org/partner

Welcome to our new Executive Director of Government Affairs, Stacey Frisk, who joins us from the Rare Disease Company Coalition. Stacey has already hit the ground running and recently moderated a panel at the @OrphanConf USA 2026 focused on the opportunities and challenges surrounding newborn screening for rare diseases. The conversation explored how policy advancements, infrastructure improvements and emerging technologies can help create a more equitable path to early diagnosis. Stacey highlighted the importance of early diagnosis in Duchenne muscular dystrophy and Solid's role in supporting the community-led effort, spearheaded by @ParentProjectMD, to advance Duchenne's nomination to the Recommended Uniform Screening Panel (RUSP). Together, these efforts reflect a commitment to expand access to early diagnosis and improve outcomes for families affected by rare diseases. #WODC #WorldOrphanDrugCongress #RareDisease #NewbornScreening #Duchenne #HealthPolicy #SolidInside #WorldOrphanUSA

We’re proud to share moments from the Team Solid at the recent Bio-Ball event! This event brought together the biotech community to support @SpOlympicsMA and the athletes who inspire us every day. It was an honor for our team to participate, compete and celebrate the power of inclusive sports. Huge thanks to the organizers and everyone who made this event unforgettable. #BIOBall #SpecialOlympics #SolidBiosciences #Community

keyboard_arrow_left Previous keyboard_arrow_right Next

It’s time to get ready for #BIO2026! We are excited to connect with industry leaders and innovators who share our goal of accelerating toward the future of precision genetic medicine. If you are interested in learning about next-generation #SolidInside technologies, including our proprietary, muscle-tropic capsid, POLARIS-101™, as well as our repository of preclinical reference data, CMC expertise and our innovative pipeline, we’d love to meet you. Our CFO, Kevin Tan, and our Head of Corporate Strategy and Business Development, Shuli Roditi-Kulak, MD, MBA, will be attending. Reach out to meet with us! #POLARIS101 #GeneTherapy, #BiotechInnovation, #GeneticResearch, #LifeSciences #PharmaPartnering #BusinessPartnering

We’re proud to support the @JettFoundation as a sponsor of the 25th Anniversary Silver Soirée on June 11. As a longstanding partner, we’re honored to stand alongside an organization that is making a meaningful difference for individuals and families impacted by Duchenne. Events like this bring the community together to celebrate progress, resilience and the work still ahead. Thank you to the Jett Foundation for your continued partnership. We look forward to an impactful evening! #SolidBiosciences #JettFoundation #SilverSoiree #Duchenne #Partnership #BiotechCommunity

Solid Biosciences is heading to the @GoldmanSachs Global Healthcare Conference in Miami on June 8. Join our President and CEO, Bo Cumbo, for a corporate presentation at 4 PM ET, where he will share updates across our pipeline and strategic priorities. Tune in here: event.webcasts.com/starthere.jsp?… #GoldmanSachs #GeneticMedicine #Biotech #Solidinside

Solid is heading to the New Directions Conference next week! We’re excited to share insights across Duchenne muscular dystrophy, Friedreich’s ataxia and our next-generation muscle-tropic capsid, POLARIS-101™. Be sure to connect with our team and tune into a featured presentation from our Head of Discovery and Translational Development, Nicolas Christoforou, Ph.D. #NewDirections #GeneticMedicine #Duchenne #FriedreichsAtaxia #MuscleBiology #SolidInside

We’re excited to partner with NanoMosaic through this co-marketing agreement to help advance the next generation of gene therapies. At Solid, we believe that unlocking the full potential of AAV requires not only innovative, precision capsid design, like our POLARIS-101™ next-generation platform, but also the ability to deeply understand and characterize what’s being delivered. By collaborating with NanoMosaic and their Tessie™ platform, we’re helping enable a more complete picture of AAV payloads – measuring capsid and transgene together and clearly distinguishing full, partial and empty particles. This collaboration reflects our commitment to advancing the broader gene therapy ecosystem through the development of next-generation technologies. We’re proud to work with NanoMosaic to expand access to solutions that can help usher in the next wave of precision genetic medicines. Read the full release: prnewswire.com/news-releases/… #GeneTherapy #AAV #Biotech #GeneticMedicine #AdvancedManufacturing #Innovation #SolidInside

Solid Biosciences will participate in the @Jefferies Global Healthcare Conference on June 3rd, where our President and CEO, Bo Cumbo, will take part in a fireside chat at 7:35 AM ET. Join via a live webcast: event.summitcast.com/view/NgCqua4VV… #JefferiesHealthcare #GeneticMedicine #Solidinside

Solid Biosciences was proud to participate in the @DPPSpain's International Congress 2026, where Patrick Gonzalez, PhD, Vice President and Head of Clinical Science, presented on SGT-003, our next-generation investigational gene therapy for Duchenne muscular dystrophy. The presentation provided an update on SGT-003, highlighting progress from both the Phase 1/2 INSPIRE DUCHENNE and the Phase 3 IMPACT DUCHENNE clinical trials. The session underscored the continued advancement of SGT-003 and its potential to deliver meaningful impact for individuals living with Duchenne. We are grateful for the opportunity to engage with the global Duchenne community and contribute to important conversations shaping the future of gene therapy and clinical innovation. #Duchenne #GeneTherapy #DuchenneCommunity #SGT003 #RareDisease #Biotech #HealthcareInnovation #SolidBiosciences